How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition

(Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Tacrine (Cognex), Bethanechol (Urecholine), Memantine (Namenda) Selegiline (Eldepryl) or any other medication for cognitive impairment. Subject has a known sensitivity to the study product. Individual has a condition the chief investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of study results or put the subject at undue risk. Contacts

2018 Clinical Trials

182. Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase. Condition or disease Intervention/treatment Phase Alzheimer Disease Cholinesterase Inhibitors Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 1205 participants Allocation: Randomized (...) Experimental: Group randomized for continuing treatment Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All randomised patients will then be followed-up for two years with regular assessment of judgment criteria

2018 Clinical Trials

183. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine (PubMed)

An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-receptor antagonist memantine. Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD. Although they share the same

Full Text available with Trip Pro

2018 Therapeutic advances in drug safety

184. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease (PubMed)

galantamine treatment. Newer antipsychotics, including paliperidone, lurasidone, aripiprazole, ziprasidone, and BL-1020, have also been reported to exert cognitive benefits in patients with schizophrenia. Dopaminergic medications were found to improve language function in patients with Parkinson's disease. However, no beneficial effects on cognitive function were observed with dopamine agonists in patients with schizophrenia. The efficacies of nicotine and its receptor modulators in cognitive improvement

Full Text available with Trip Pro

2018 Frontiers in Psychiatry

185. New 2-Aryl-9-methyl-β-carbolinium salts as Potential Acetylcholinesterase Inhibitor agents: Synthesis, Bioactivity and Structure–Activity Relationship (PubMed)

the excellent activity with IC50 values of 0.11-0.76 μM and high selectivity toward AChE relative to butyrylcholinesterase (BChE), superior to galantamine (IC50 = 0.79 μM), a selective AChE inhibitor drug. Kinetic analysis showed that the action mechanisms of both compounds B and A are a competitive inhibition model. Structure-activity relationship analyses showed that the C = N+ moiety is a determinant for the activity. Substituents at 6, 7 or 4' site, the indole-N-alkyl and the aromatization of the C-ring

Full Text available with Trip Pro

2018 Scientific reports

186. What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink (PubMed)

their first prescription for each drug class-namely, acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine, galantamine) and N-methyl-D-aspartate (NMDA) receptor antagonists (memantine). Trend analysis using joinpoint models was then applied to identify up to two trend changes per treatment of interest.The overall trend was for increasing prescriptions in each drug class over the period in which they were studied. This was indicated by the average monthly percentage change, which was 6.0% (95

Full Text available with Trip Pro

2018 Alzheimer's research & therapy

187. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis (PubMed)

effects model.We identified 37 studies (n=1,574): 14 donepezil-based (n=568), 10 galantamine-based (n=371), 4 rivastigmine-based (n=146), and 9 memantine-based (n=489) studies. Pooled ADD+AP treatments were superior to placebo+AP in improving the overall symptoms (24 studies, 1,069 patients: standardized mean difference [SMD]=-0.34, 95% confidence interval [CI]=-0.61 to -0.08, P=0.01), negative symptoms (24 studies, 1,077 patients: SMD=-0.62, 95% CI=-0.92 to -0.32, Pcorrected=0.00018), and MMSE scores

Full Text available with Trip Pro

2018 International Journal of Neuropsychopharmacology

188. ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

caregiver or other appropriate knowledgeable informant who can reliably report on daily activities and function and signs the informed consent for participation as such. Patient must be a good surgical candidate for placement of a deep brain stimulator as judged by the DBS surgical team. Fluency (oral and written) in the language in which standardized tests will be administered. The patient is taking a stable dose of cholinesterase inhibitor (AChEI) medication (donepezil, galantamine, or rivastigmine

2018 Clinical Trials

189. DHA Brain Delivery Trial

in the last 3 months > 200 mg/day of DHA consumption using a validated questionnaire Use of donepezil, rivastigmine, galantamine and/or memantine Alcohol or drug abuse A concomitant serious disease such as active cancer treatment or HIV. Participation in a clinical trial in the last 30 days Use of anticoagulants such as Plavix or Coumadin or the newer generation blood thinners. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor

2018 Clinical Trials

190. Examining the Effects of One-Month Probiotic Treatment on Mental Fatigue

, dabigatran, ticagrelor non-steroidal anti-inflammatory drugs (NSAIDS; excluded only for daily use) over-the-counter sleep medication (not categorized as sedatives, hypnotics or anti-depressants) anti-cholinergic drugs or acetylcholinesterase inhibitors: bethanechol (Urecholine), donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl), neostigmine (Prostigmin) anti-histamines that cause drowsiness (eg. Ranitidine) pseudoephedrine and phenylephrine Currently taking (from day of screening onwards

2018 Clinical Trials

191. Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

will undergo screening assessments to determine eligibility. This study will enroll patients who are ≥50 years of age with mild to moderate Alzheimer's Disease and on a stable treatment of donepezil, rivastigmine or galantamine for ≥3 months. Patients will be randomized (using a balanced block randomization schedule) to one of two treatment groups: Group A: 10-mg Montelukast buccal film Group B: Matching placebo buccal film In addition to the global NTB composite, patients will also be evaluated using (...) Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate Alzheimer's Disease. MMSE score of 14 - 22 CT or MRI within 18 months prior to screening indicating clinical phenotype of Alzheimer's Disease Treated daily with donepezil, rivastigmine or galantamine for ≥ 3 months All other medications for chronic conditions should have been at a stable dose for at least 2 weeks prior to first dose. No clinically meaningful abnormalities on electrocardiogram (ECG), physical examination and clinical

2018 Clinical Trials

192. Quality of the Management of Diabetes in Elderly People With Dementia in France

by the National Library of Medicine related topics: related topics: resources: Groups and Cohorts Go to Group/Cohort Intervention/treatment Case : ADRS group Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: "F00-F03", "G30", or "G31"), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine

2018 Clinical Trials

193. An Open Pilot Trial of BHV-4157

is prohibited 30 days prior to screening and during the study; Use of aminopyridine is prohibited 30 days prior to screening and during the study; Use of tricyclic antidepressants and mono-amine-oxidase (MAO) inhibitors are prohibited 30 days prior to screening and during the study; Use of any approved treatments for Alzheimer's Disease (AD). Subjects should be free of such medications (donepezil, galantamine, rivastigmine and memantine) for at least 3 months prior to Baseline with no plans to start

2018 Clinical Trials

194. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial (PubMed)

with vascular damage to the cholinergic system will in turn respond to a cholinergic challenge.The STREAM-VCI is a single center, double blind, three-way cross-over trial among 30 people with VCI, in which subjects received a single dose of galantamine, methylphenidate, or placebo on separate occasions. The most important inclusion criteria were a diagnosis of VCI with a Mini-Mental State Examination score of ≥16 and a Clinical Dementia Rating of 0.5-1.0. For each person, the challenges consisted (...) of a single 16 mg dose of galantamine, 10 mg of methylphenidate, and placebo, in random order on three separate visits. Change in performance in executive functioning and memory was assessed directly after the challenge using standardized neuropsychological tests. We will correlate a positive response to the cholinergic and monoaminergic treatment with differences in structural and functional connectivity at baseline using structural magnetic resonance imaging (MRI), diffusion tension MRI, and resting

Full Text available with Trip Pro

2018 JMIR Research Protocols

195. Strategies for Continued Successful Treatment in Patients with 
Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents (PubMed)

Strategies for Continued Successful Treatment in Patients with 
Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents Alzheimer's disease (AD) is the most common cause of dementia, characterized by a progressive decline in cognition and function. Current treatment options for AD include the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine, as well as the N-methyl-Daspartate receptor antagonist memantine. Treatment guidelines recommend the use

Full Text available with Trip Pro

2018 Current Alzheimer research

196. Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice (PubMed)

Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice Zymosan, a natural compound, provokes acute peritonitis and multiple organ dysfunction that affects the kidney, beside other organs via exaggerated inflammatory response. The aim of the present study is to test the role of cholinergic anti-inflammatory pathway (CAP) in alleviating acute kidney injury (AKI) induced by zymosan in BALB/c mice, using galantamine, a cholinesterase (...) inhibitor, known to act via α7 nicotinic acetylcholine receptor (α7 nAChR) to stimulate CAP. Galantamine verified its anti-inflammatory effect by elevating acetylcholine (ACh) level, while abating the interleukin-6/ janus kinase 2 (Y1007/1008)/ signal transducer and activator of transcription 3 (Y705) (IL-6/ pY(1007/1008)-JAK2/ pY705-STAT3) inflammatory axis, with a consequent inhibition in suppressor of cytokine signaling 3 (SOCS3). This effect entails also the nuclear factor-kappa B (p65)/ high

Full Text available with Trip Pro

2018 Scientific reports

197. Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease (PubMed)

carried out virtual screening of drug-like molecules from Chemical Diversity Database particularly CNS-BBB compounds, to identify potential inhibitors using Glide docking program. Top ranking ten compounds, which have lower Glide Score when compared to known drugs (Tacrine and Galantamine) for AChE. For top three molecules MD simulation was carried out and calculated binding free energy. We report the best binding compounds with AChE compared to known drugs (Taine and Galantamine) for AD. We further (...) ligands Tacrine and Galantamine having -119.65 and -142.18 kJ/mol respectively. Thus these molecules can be very novel potential inhibitors against AChE involved in Alzheimer's disease.

Full Text available with Trip Pro

2018 Bioinformation

198. Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy (PubMed)

, among which galantamine is the only naturally occurring substance. However, several plant species producing diverse classes of alkaloids, coumarins, terpenes, and polyphenols have been assessed for their anti-AChE activity, becoming potential candidates for new anti-AD drugs. Therefore, this mini-review aimed to recapitulate last decade studies on the anti-AChE activity of plant species, their respective extracts, as well as isolated compounds. The anti-AChE activity of extracts prepared from 54

Full Text available with Trip Pro

2018 Frontiers in pharmacology

199. Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review (PubMed)

Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review The increasing prevalence of Alzheimer's disease (AD) demands more effective drugs, which are still unclear. The aim of this study is to compare the effectiveness of six drugs, such as donepezil, rivastigmine, galantamine, memantine, huperzine-A, and tacrine, in senior AD patients and identify the most effective one to improve patients' cognitive function.A system of search strategies (...) the trials included.Among the 35 trials included, no obvious heterogeneity (I2=0.0%, P=0.583) was revealed according to the pooled data for cognition in NMA and the mean difference (MD) of memantine (MD=1.7, 95% CI: 0.73, 2.8) showed that the memantine was significantly efficacious in the treatment group in terms of MMSE. Followed by galantamine, huperzine-A, rivastigmine, tacrine, and donepezil.As the first NMA comparing the major drugs in market for AD, our study suggests that memantine might have

Full Text available with Trip Pro

2018 Clinical interventions in aging

200. Open-label, PK and Safety Study in Mild-to-moderate Alzheimer's Disease Patients

at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care General health status acceptable for participation in the study Fluency (oral and written) in English or Spanish If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months (90 days) before screening and with continuous dosing for at least 3 months. If receiving donepezil, receiving any dose lower than 23 mg once daily. The patient

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>